Krystal Biotech, Inc. Forecast, price target & analysts
Krystal Biotech, Inc. Target price 2025 - Analyst rating & recommendation
Krystal Biotech, Inc. Classifications & Recommendation:
Krystal Biotech, Inc. Price Target
| Target Price | $222.36 |
| Price | $218.00 |
| Potential |
2.00%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Krystal Biotech, Inc. 2026 .
The average Krystal Biotech, Inc. target price is $222.36.
This is
2.00%
register free of charge
$267.75
22.82%
register free of charge
$199.98
8.27%
register free of charge
|
|
| A rating was issued by 18 analysts: 16 Analysts recommend Krystal Biotech, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Krystal Biotech, Inc. stock has an average upside potential 2026 of
2.00%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 290.52 | 390.25 |
| 473.02% | 34.33% | |
| EBITDA Margin | 37.57% | 39.36% |
| 120.66% | 4.75% | |
| Net Margin | 30.69% | 37.83% |
| 42.36% | 23.27% |
13 Analysts have issued a sales forecast Krystal Biotech, Inc. 2025 . The average Krystal Biotech, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Krystal Biotech, Inc. EBITDA forecast 2025. The average Krystal Biotech, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Krystal Biotech, Inc. Analysts have issued a net profit forecast 2025. The average Krystal Biotech, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 3.00 | 5.09 |
| 669.23% | 69.67% | |
| P/E | 42.80 | |
| EV/Sales | 14.33 |
14 Analysts have issued a Krystal Biotech, Inc. forecast for earnings per share. The average Krystal Biotech, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Krystal Biotech, Inc....
Current Krystal Biotech, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Chardan Capital |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 15 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 22 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 22 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Oct 17 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 15 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 22 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 22 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 05 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
